Martin Bergstrand

Martin Bergstrand

Auto-generated profile, based on publicly available information

Martin Bergstrand

Pharmetheus AB Uppsala Sweden

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2011 in The AAPS Journal
Verified
Journal Article
Open access
PDF file
MBMartin Bergstrand
Martin Bergstrand
AHAndrew C. Hooker
Andrew C. Hooker
JWJohan E. Wallin
Johan E. Wallin
MKMats O. Karlsson
Mats O. Karlsson
Informative diagnostic tools are vital to the development of useful mixed-effects models. The Visual Predictive Check (VPC) is a popular tool for evaluating the performance of population PK and PKPD...

19 May 2009 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
MBMartin Bergstrand
Martin Bergstrand
MKMats O. Karlsson
Mats O. Karlsson

1 June 2014 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
EKEdmund S. Kostewicz
Edmund S. Kostewicz
LALeon Aarons
Leon Aarons
MBMartin Bergstrand
Martin Bergstrand
MBMichael B. Bolger
Michael B. Bolger
AGAleksandra Galetin
Aleksandra Galetin
JDJennifer Dressman
Jennifer Dressman

11 October 2016 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
ADAnne-Gaëlle Dosne
Anne-Gaëlle Dosne
MBMartin Bergstrand
Martin Bergstrand
KHKajsa Harling
Kajsa Harling
MKMats O. Karlsson
Mats O. Karlsson
Taking parameter uncertainty into account is key to make drug development decisions such as testing whether trial endpoints meet defined criteria. Currently used methods for assessing parameter uncertainty in NLMEM have limitations, and there is a lack of diagnostics for when these limitations occur. In this work, a method based on sampling importance resampling (SIR) is proposed, which has the advantage of being free of distributional assumptions and does not require repeated parameter estimation. To perform SIR, a high number of parameter vectors are simulated from a given proposal uncertainty distribution. Their likelihood given the true uncertainty is then approximated by the ratio between the likelihood of the data given each vector and the likelihood of each vector given the proposal distribution, called the importance ratio. Non-parametric uncertainty distributions are obtained by resampling parameter vectors according to probabilities proportional to their importance ratios. Two simulation examples and three real data examples were used to define how SIR should be performed with NLMEM and to investigate the performance of the method. The simulation examples showed that SIR was able to recover the true parameter uncertainty. The real data examples showed that parameter 95 % confidence intervals (CI) obtained with SIR, the covariance matrix, bootstrap and log-likelihood profiling were generally in agreement when 95 % CI were symmetric. For parameters showing asymmetric 95 % CI, SIR 95 % CI provided a close agreement with log-likelihood profiling but often differed from bootstrap 95 % CI which had been shown to be suboptimal for the chosen examples. This work also provides guidance towards the SIR workflow, i.e.,which proposal distribution to choose and how many parameter vectors to sample when performing SIR, using diagnostics developed for this purpose. SIR is a promising approach for assessing parameter uncertainty as it is applicable in many situations where other methods for assessing parameter uncertainty fail, such as in the presence of small datasets, highly nonlinear models or meta-analysis.

31 October 2011 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MTMirjam N. Trame
Mirjam N. Trame
MBMartin Bergstrand
Martin Bergstrand
MKMats O. Karlsson
Mats O. Karlsson
JBJoachim Boos
Joachim Boos
GHGeorg Hempel
Georg Hempel
Purpose: To evaluate the best method for dosing busulfan in children, we retrospectively analyzed two different data sets from three different dosing regimens by means of population pharmacokinetics using NONMEM. Experimental Design: The development data set consisted of plasma samples from 94 children, in the age range of 0.4 to 18.8 years, receiving either oral or intravenous busulfan. The external model evaluation data set comprised 24 children, in the age range of 0.1 to 18.9 years, who belonged to the once-daily intravenous busulfan dosing regimen. A one-compartment model with first-order absorption using body surface area (BSA) or allometric body weight (BW) as covariate on clearance (CL) and BW as covariate on volume of distribution (V) were used to describe the results sufficiently. In addition to interindividual variability on all pharmacokinetic parameters, interoccasion variability was included for CL and V. Results: CL values in the present study did not reflect the shape of the CL versus weight curve reported in previous investigations. By external model evaluation, we were able to confirm these findings. Furthermore, bioavailability was calculated to be between 93% and 99% for the development data set. On the basis of the final models, we simulated two dosing schemes according to allometric BW and BSA showing that we estimated to include about 30% more patients into the proposed therapeutic area under the curve (AUC) range of 900 to 1,500 μM*min and could, furthermore, achieve a reduction in the AUC variability when dosed according to the labeled European Medicines Agency (EMA) dosing recommendation. Conclusion: We recommend a BSA or an allometric BW dosing regimen for individualizing busulfan therapy in children to reduce variability in busulfan exposure and to improve safety and efficacy of busulfan treatment. Clin Cancer Res; 17(21); 6867–77. ©2011 AACR.

12 April 2016 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
MMMarkus R. Meyer
Markus R. Meyer
MBMadeleine Pettersson Bergstrand
Madeleine Pettersson Bergstrand
AHAnders Helander
Anders Helander
OBOlof Beck
Olof Beck